Abstract:Background: The WHO Essential Medicines List (EML) identifies priority medicines that are most important to public health. Over time, the EML has included an increasing number of cancer medicines. We aimed to investigate whether the cancer medicines in the EML are aligned with the priority medicines of frontline oncologists worldwide, and the extent to which these medicines are accessible in routine clinical practice. Methods: This international, cross-sectional survey was developed by investigators from a range of clinical practice settings across low-income to high-income countries, including members of the WHO Essential Medicines Cancer Working Group. A 28-question electronic survey was developed and disseminated to a global network of oncologists in 89 countries and regions by use of a hierarchical snowball method; each primary contact distributed the survey through their national and regional oncology associations or personal networks. The survey was open from Oct 15 to Dec 7, 2020. Fully qualified physicians who prescribe systemic anticancer therapy to adults were eligible to participate in the survey. The primary question asked respondents to select the ten cancer medicines that would provide the greatest public health benefit to their country; subsequent questions explored availability and cost of cancer medicines. Descriptive statistics were used to compare access to medicines between low-income and lower-middle-income countries, upper-middle-income countries, and high-income countries. Findings: 87 country-level contacts and two regional networks were invited to participate in the survey; 46 (52%) accepted the invitation and distributed the survey. 1697 respondents opened the survey link; 423 were excluded as they did not answer the primary study question and 326 were excluded because of ineligibility. 948 eligible oncologists from 82 countries completed the survey (165 [17%] in low-income and lower-middle-income countries, 165 [17%] in upper-middle-income countries, and 618 [65%] in high-income countries). The most commonly selected medicines were doxorubicin (by 499 [53%] of 948 respondents), cisplatin (by 470 [50%]), paclitaxel (by 423 [45%]), pembrolizumab (by 414 [44%]), trastuzumab (by 402 [42%]), carboplatin (by 390 [41%]), and 5-fluorouracil (by 386 [41%]). Of the 20 most frequently selected high-priority cancer medicines, 19 (95%) are currently on the WHO EML; 12 (60%) were cytotoxic agents and 13 (65%) were granted US Food and Drug Administration regulatory approval before 2000. The proportion of respondents indicating universal availability of each top 20 medication was 9-54% in low-income and lower-middle-income countries, 13-90% in upper-middle-income countries, and 68-94% in high-income countries. The risk of catastrophic expenditure (spending >40% of total consumption net of spending on food) was more common in low-income and lower-middle-income countries, with 13-68% of respondents indicating a substantial risk of catastrophic expenditures for each of the top 20 medications in lower-middle-income countries versus 2-41% of respondents in upper-middle-income countries and 0-9% in high-income countries. Interpretation: These data demonstrate major barriers in access to core cancer medicines worldwide. These findings challenge the feasibility of adding additional expensive cancer medicines to the EML. There is an urgent need for global and country-level policy action to ensure patients with cancer globally have access to high priority medicines. Funding: None.

WHO Includes 16 New Cancer Drugs on List of Essential Medicines.

Overall Survival Benefits of Cancer Drugs in the WHO Model List of Essential Medicines, 2015–2021

A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications

Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey

WHO Priority List of Medical Devices for Cancer Management

Which Drugs Should Be on the Essential Medicines List?

Measuring the value of the WHO Model list of essential medicines

Five Cancer Drugs Back on NHS List after Deals with Drug Companies

Evidence of Clinical Benefit of WHO Essential Anticancer Medicines for Children, 2011–2021

Sales of Anti-Cancer Medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand.

Essential cancer medicines and cancer outcomes: Cross-sectional study of 124 countries

China issues the National Essential Medicines List (2018 edition): Background, differences from previous editions, and potential issues.

Drug therapy of cancer

Nhs England Drops 16 Medicines From Cancer Drugs Fund

WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines

Policies and programs to facilitate access to targeted cancer therapies in Thailand

An update of new small-molecule anticancer drugs approved from 2015 to 2020

The Disconnect between Clinical Guidelines and Reality: The Case of Trastuzumab

Differences in reimbursement listing of anticancer therapies in China: an observational study

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review